Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425682 | 0.86 | EPHX1 (0.42) | EPHX1 | |
| SCHEMBL14279765 | 0.82 | KMT2A (0.32) | EPHX1KMT2A | |
| SCHEMBL1811298 | 0.80 | KMT2A (0.32) | KMT2A | |
| SCHEMBL31303847 | 0.79 | EPHX1 (0.53) | EPHX1 | |
| SCHEMBL342676 | 0.79 | — | — | |
| SCHEMBL13537074 | 0.78 | KMT2A (0.34) | KMT2A | |
| SCHEMBL21283653 | 0.78 | EPHX1 (0.56) | EPHX1 | |
| SCHEMBL15565885 | 0.77 | KMT2A (0.35) | EPHX1KMT2A | |
| SCHEMBL15635603 | 0.76 | KMT2A (0.30) | KMT2A | |
| SCHEMBL31721432 | 0.76 | KMT2A (0.30) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025230799-A2 | CYCLOALKYL- AND PIPERIDINYL-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025226895-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS COMPRISING SUBSTITUTED OR MODIFIED DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONES | SEPTERNA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608810-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024091498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| WO-2009136850-A1 | MUSCARINIC RECEPTOR AGONITS USEFUL IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | WO | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| US-4461902-A | BLOOD LIPID AND SUGAR LOWERING AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-07-24 | — | — | US | disclosed |
| EP-0084926-A1 | Thiazolidine derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1983-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | EPHX1 3897/4885KMT2A 3560/4885 |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | CACNA1A, SCN10A, OPRM1 | EPHX1 1508/4885KMT2A 2482/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | EPHX1 3897/4885KMT2A 3560/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | EPHX1 4831/4885KMT2A 4097/4885 |
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | EPHX1 3462/4885KMT2A 1339/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | EPHX1 3897/4885KMT2A 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.